Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 January 2002

Drug-induced liver damage - a three-year study of patients from one gastroenterological department.

Lukasz Biernat, Marek Hartleb, Anna Kochel

Med Sci Monit 2002; 8(4): CR292-296 :: ID: 420865

Abstract

BACKGROUND: The aim of our study was to analyze drug-induced liver diseaseover a 3-year period in one gastroenterological department. MATERIAL/METHODS: International consensusstandard definitions and criteria for assessing causality of adverse drug reactions were applied to allpatients with abnormal hepatic test results. RESULTS: Drugs were implicated in hepatic injury in 14 patients(8 females) in whom causal relationship between drug and liver disease was definite or highly probable.The drugs responsible were amoxicillin with clavulanic acid (3 cases), fluvastatin and pravastatin (3cases), antituberculous drugs (2 cases), estrogens, roxithromycin, asacol, satolol, enalapril and thiamazol.A total of 78.6% (11 cases) were classified as hepatocellular or mixed hepatitis, while cholestatic injurywas found in 21.4% (3 cases). There were no lethal or severe (prothrombin < 50%) hepatic drug reactions.In 13 patients the course of liver disease after withdrawal of the offensive drug was either acute orprotracted, while in one patient there was chronic cholestasis (>3 years) resulting from injury to interlobularbile ducts by amoxicllin with clavulanic acid. CONCLUSIONS: A thorough history of drug intake shouldbe taken in all patients presenting with abnormal hepatic test results. Amoxicillin & clavulanic acid,cholesterol-lowering and antituberculin drugs were the most frequent hepatotoxic factors in our patients.In a majority of cases the liver injury was not severe, and resolved after prompt withdrawal of the responsibledrug.

Keywords: Anti-Bacterial Agents, Anti-Inflammatory Agents, Non-Steroidal, Anticholesteremic Agents, Antitubercular Agents, Comorbidity, enalapril, Estrogens, Fatty Liver, Hepatitis, Toxic, Liver Diseases, Mesalamine

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750